Structural modifications in the arterial wall during physiological aging and as a result of diabetes mellitus in a mouse model: Are the changes comparable?;Les modifications de la paroi vasculaire liées au vieillissement et celles liées au diabète sont-elles comparables ?

Diabetes and Metabolism

Volumn 37, Issue 2, 2011, Pages 106-111

  Prevost G ^a,b   Bulckaen, H ^a,c   Gaxatte, C ^a   Boulanger, E ^a   Beraud G ^a   Creusy, C ^c   Puisieux, F ^a   Fontaine, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Lille Catholic Institute Hospital   (France)

Author keywords

Diabetes; Endothelium; Intima media; Vascular aging; Vasodilatation

Indexed keywords

ACETYLCHOLINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; PHENYLEPHRINE; STREPTOZOCIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM; INTIMA; MALE; MORPHOLOGY; MOUSE; NONHUMAN; VASODILATATION; WESTERN BLOTTING;

EID: 79955050258     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.08.005     Document Type: Article

References (43)

1. Orlandi A., Bochaton-Piallat M.L., Gabbiani G., Spagnoli L. Aging, smooth muscle cells and vascular pathobiology: implications for atherosclerosis. Atherosclerosis 2006, 188:221-230.
2. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 14:73-78.
3. Booth G.L., Kapral M.K., Fung K., Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368:29-36.
4. Balkau B., Hu G., Qiao Q., Tuomilehto J., Borch-Johnsen K., Pyörälä K., et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004, 47:2118-2128.
5. Winer N., Sowers J.R. Epidemiology of diabetes. J Clin Pharmacol 2004, 44:397-405.
6. Schalkwijk C., Stehouwer C. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005, 109:143-159.
7. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009, 73:595-601.
8. Koga T, Takata Y, Kobayashi K, Takishita S, Yamashita Y, Fujishima M. Ageing suppresses endothelium-dependent relaxation and generates contraction mediated by the muscarinic receptors in vascular smooth muscle of normotensive Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens 1988;6(Suppl):S243-5.
9. Matz R.L., Schott C., Stoclet J.C., Andriantsitohaina R. Age-related endothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. Physiol Res 2000, 49:11-18.
10. Goto K., Fujii K., Onaka U., Abe I., Fujishima M. Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension 2000, 36:581-587.
11. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., Vanhoutte P.M. Endothelial dysfunction in diabetes. Br J Pharmacol 2000, 130:963-974.
12. Bulckaen H., Prévost G., Boulanger E., Robitaille G., Roquet V., Gaxatte C., et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Am J Physiol Heart Circ Physiol 2008, 294:1562-1570.
13. Simonsen U., Rodriguez-Rodriguez R., Dalsgaard T., Buus N.H., Stankevicius E. Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation. Pharmacol Rep 2009, 61:105-115.
14. Kwan C., Wang R., Beazley J., Lee R. Alterations of elastin and elastase-like activities in aortae of diabetic rats. Biochim Biophys Acta 1988, 967:322-325.
15. Greenwald S. Ageing of the conduit arterie. J Pathol 2007, 211:157-172.
16. Brüel A., Oxlund H. Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Atherosclerosis 1996, 127:155-165.
17. Heickendorff L., Ledet T., Rasmussen L.M. Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia 1994, 37:286-292.
18. Renard C.B., Kramer F., Johansson F., Lamharzi N., Tannock L.R., von Herrath M.G., et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004, 114:659-668.
19. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type-2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
20. Tabas I., Williams K.J., Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
21. Yan R.T., Anderson T.J., Charbonneau F., Title L., Verma S., Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005, 45:1980-1986.
22. Corman B., Duriez M., Poitevin P., Heudes D., Bruneval P., Tedgui A., et al. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A 1998, 95:1301-1306.
23. Nishikawa T., Edelstein D., Du X., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
24. Forbes J., Yee L., Thallas V., Lassila M., Candido R., Jandeleit-Dahm K., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004, 53:1813-1823.
25. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419:31-40.
26. Boulanger E., Wautier M.P., Wautier J.L., Boval B., Panis Y., Wernert N., et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002, 61:148-156.
27. Hudson B.I., Schmidt A.M. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004, 21:1079-1086.
28. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung, which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997.
29. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
30. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm 2005, 11:2279-2299.
31. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889-9897.
32. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685-E694.
33. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996, 97:238-243.
34. Wautier J.L., Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95:233-238.
35. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432-438.
36. Xu B., Chibber R., Ruggiero D., Kohner E., Ritter J., Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003, 17:1289-1291.
37. Archibald V., Cotter M.A., Keegan A., Cameron N.E. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn Schmiedebergs Arch Pharmacol 1996, 353:584-591.
38. Pieper G.M. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999, 42:204-213.
39. Vanhoutte P.M., Shimokawa H., Tang E., Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009, 196:193-222.
40. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814.
41. Giardino I., Fard A.K., Hatchell D.L., Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998, 47:1114-1120.
42. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997, 272:16498-16506.
43. Madamanchi N.R., Runge M.S. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007, 100:460-473.